Did Qiagen beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Qiagen next quarter?

What does Qiagen do and what are its main business segments?

What is Qiagen's latest dividend and current dividend yield?

What guidance did Qiagen's management provide for the next earnings period?

What is Qiagen's gross profit margin?

What were the key takeaways from Qiagen’s earnings call?

What were the key takeaways from Qiagen's earnings call?

- **Revenue Beat**: Q3 net sales $533M (+6%), core sales +6% CER. Adjusted EPS $0.61 vs. $0.58 target.
- **Strategic Moves**: $500M Parse acquisition for single-cell tech; $500M share buyback announced.
- **Profitability**: 29.6% operating margin, 9.2% R&D investment.
- **Key Growth Drivers**: QIAstat +11%, QuantiFERON +11%, QDI double-digit growth.
- **2028 Ambitions**: 7% CAGR, 31% margin on track despite headwinds.
- **Tariff Mitigation**: 90bps margin impact, but 2025 EPS EPS raised to $2.38.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 net sales rose 6% to $533 million (5% at constant exchange rates), with core sales up 6% CER. Adjusted EPS was $0.61, exceeding the outlook of $0.58.
- **Strategic Acquisitions**: Announced acquisition of Parse Biosciences for $500 million, expanding into single-cell analysis with instrument-free combinatorial barcoding technology. Also, a $500 million synthetic share repurchase set for January 2026.
- **Key Product Performances**: 
  - QIAstat diagnostics grew 11% CER, driven by 150 new placements and double-digit consumable growth.
  - QuantiFERON grew 11% CER, benefiting from latent TB conversion from skin tests.
  - Sample Technologies returned to growth (3% CER) on automated consumables demand.
  - QIAGEN Digital Insights (QDI) delivered double-digit growth, enhanced by Genoox integration.
- **2028 Ambitions**: On track for 7% CAGR in core sales and 31% adjusted operating margin by 2028, despite currency and integration headwinds.

**【CFO Financial Commentary】**
- **Profitability**: Adjusted operating income margin of 29.6% (30% CER), absorbing 150bps of currency headwinds. R&D investment at 9.2% of sales, supporting new product launches.
- **Cash Flow**: Underlying operating cash flow of $466 million for 9 months, with free cash flow of $336 million.
- **Balance Sheet**: Strong cash position enabling $500 million share repurchase and $1 billion+ returns to shareholders by 2028. Leverage ratio expected to move towards industry average of 2x in 2026.
- **Tariff Impact**: U.S. tariffs creating 90bps headwind on gross margin, but mitigated through pricing and operational efficiency.

**【Q&A Highlights】**
- **Parse Acquisition**: Expected to be accretive by 2028, with $40 million revenue in 2026 and 3,000+ lab installations globally. Synergies with QDI for AI-driven single-cell data interpretation.
- **QIAstat Growth**: 11% Q3 growth despite seasonal softness, driven by GI and meningitis panels. U.S. placements in 6 months exceeded 2024 full-year volume.
- **Tariff Mitigation**: Surcharge pass-through successful, with no material demand delay. 2025 EPS guidance raised to $2.38 CER (+$0.10).
- **2026 Outlook**: Core sales growth 5-6% CER, adjusted EPS $2.38 CER. Shutdown impact on U.S. academic spending factored into Q4 guidance.

Qiagen N.V. (QGEN) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 net sales up 7% to $534 million, core sales +6% CER. Full-year target raised to 4-5% CER.
- **QIAstat Momentum**: 41% CER growth, surpassing 150 systems/Q2 target, with U.S. placements exceeding 2024 full-year levels.
- **Profitability**: Operating margin 29.9%, EPS $0.60 vs. target. 2025 EPS target $2.35 CER.
- **Shareholder Returns**: $54M dividend paid, $500M share buyback authorized. Total returns $650M+ since 2024.
- **Risks**: Tariff headwinds (90 bps gross margin), cautious capital spending in life sciences, China market weakness.

**【CEO Summary Section】**
- **Q2 2025 Performance**: Net sales rose 7% to $534 million (6% at constant exchange rates), with core sales growing 6% CER. Adjusted diluted EPS was $0.60, exceeding targets.
- **Growth Pillars**: 
  - QIAstat-DX grew 41% CER, driven by instrument placements (exceeded 150 systems/Q2 target) and menu expansion.
  - QuantiFERON grew 11% CER, with momentum in EMEA and Americas.
  - QIAcuity saw double-digit growth in consumables, despite soft instrument sales.
  - QIAGEN Digital Insights maintained momentum post-Genoox acquisition.
- **Upgraded Outlook**: Full-year 2025 net sales target raised to 4-5% CER (from 4%), with core portfolio growth at 5-6% CER. Adjusted EPS target confirmed at $2.35 CER.
- **Shareholder Returns**: $54 million dividend paid in Q2, with $500 million share repurchase authorization. Total returns to shareholders since 2024: $650 million.

**【CFO Financial Commentary】**
- **Profitability**: Adjusted operating margin rose to 29.9% (28.4% in Q2 2024), driven by efficiency initiatives. Gross margin declined to 66.7% due to tariffs and currency impacts.
- **Cash Flow**: Operating cash flow $301 million (flat vs. Q2 2024), with free cash flow $270 million. SAP system upgrade investments offset by working capital improvements.
- **Tariff Impact**: 90 basis points headwind on gross margin for 2025, with ongoing mitigation efforts.
- **Tax Rate**: 20% in Q2, targeting 19% for the year.

**【Q&A Key Highlights】**
- **QIAstat Growth**: 41% CER driven by respiratory testing (70% of market), GI/meningitis panel expansion, and U.S. instrument placements surpassing 2024 full-year levels.
- **QIAcuity Outlook**: Targeting 600-1,000 systems for 2025, confident in pharma partnerships (e.g., ID Solutions, Tracer Biotechnologies) to drive oncology applications.
- **Competitive Dynamics**: QIAcuity's simplicity and automation优势 seen as key against Bio-Rad's Stilla acquisition.
- **China Challenges**: Sales down low teens CER, with no expected recovery before H2 2026. Focus on automation and clinical solutions.
- **M&A Strategy**: Pipeline strong, with focus on synergistic bolt-ons (e.g., Genoox) and 3-year accretion pathway.
- **Tariff Mitigation**: Internal supply chain adjustments and customer cost-sharing reducing impact, but 90 bps gross margin headwind remains.


Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript

- **Q1 2025 outperformance**: 7% CER sales growth vs. 4% full-year target, driven by QIAstat (+37%) and QuantiFERON (+16%).
- **Margin expansion**: Operating margin 29.8% (vs. 25.6% last year), targeting >31% by end-2025.
- **Shareholder returns**: $0.25 dividend + $500M buyback, plus $600M+ returned since 2024.
- **Growth engines**: QIAcuity (12-target multiplexing), QIAsymphony Connect launch, and 35+ pharma CDx partnerships.
- **Risk management**: Mitigated tariffs via inventory, offset weaker China (-2% CER) with Americas/EMEA growth.


**【CEO Opening Remarks】**
- Q1 2025 net sales: $483M (+7% CER vs. Q1 2024), exceeding guidance of at least $0.50 CER for adjusted EPS.
- Key product highlights:
  - QIAstat-Dx sales +37% CER, driven by new panels and instrument placements.
  - QuantiFERON TB test sales +16% CER, targeting $600M by 2028.
  - QIAcuity digital PCR system adoption accelerating with 12-target multiplexing capability.
- Shareholder returns: Proposed $0.25 annual dividend + $500M share buyback authorization.
- 2025 outlook reaffirmed: 4% CER sales growth, $2.35 CER adjusted EPS.

**【CFO Financial Details】**
- Adjusted operating margin: 29.8% (vs. 25.6% Q1 2024), driven by:
  - 11% CER growth in diagnostic solutions (QIAstat, QuantiFERON).
  - 14% CER growth in PCR Technologies (QIAcuity, consumables).
  - Portfolio optimization (NeuMoDx phase-out completion mid-2025).
- Free cash flow: $96M (vs. $133M Q1 2024), supporting SAP system upgrade.
- Regional performance:
  - Americas +9% CER, EMEA +8% CER, APAC -2% CER (China weakness offset by Japan growth).
- 2025 guidance: Target adjusted operating margin >31% (vs. 2023 level of 26.5%).

**【Q&A Highlights】**
- **Profitability drivers**: Efficiency initiatives (400+ cost-saving projects) and portfolio optimization (discontinuing low-margin products).
- **China risk**: Minimal impact (4% of sales), but challenging regulatory environment.
- **Instrument recovery**: QIAcuity 8-plate system adoption in pharma, QIAsymphony Connect launch Q4 2025.
- **M&A pipeline**: Multiple bolt-on opportunities in bioinformatics and diagnostics.
- **Tariff mitigation**: Pre-positioned inventory, shared costs with customers.
- **Digital Insight growth**: SaaS transition underway, 15%+ long-term target.


Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript

- **Q4 2024 Beat**: $521M sales (+3% CER), $0.61 EPS vs $0.60 target. Full-year 2024: $1.985B sales, $2.19 EPS.
- **Growth Drivers**: QIAstat-Dx (+25% Q4), QuantiFERON (+14% Q4), digital PCR expansion.
- **2025 Outlook**: 4% sales growth, $2.28 EPS, >30% operating margin.
- **Key Wins**: QIAstat FDA panels, QuantiFERON U.S. pediatric guidelines, 1,000+ QIAconnect placements.
- **Margin Expansion**: 150+ bps 2025, 31%+ by 2028. $506M 2024 free cash flow, $1B+ returns by 2028.
- **Risks**: China sales decline, cautious instrument spending, NeuMoDx phase-out ($30M 2024, $70M 2025).

**【CEO Opening Remarks】**
- Q4 2024 net sales of $521M (+3% CER) and adjusted EPS of $0.61, both exceeding guidance. Full-year 2024 sales of $1.985B (+1.7% CER) and EPS of $2.19, surpassing targets.
- Key growth drivers: QIAstat-Dx (+25% Q4 CER, 660+ new systems), QuantiFERON (+14% Q4 CER), and digital PCR expansion.
- 2025 outlook: 4% CER sales growth (5% core ex-NeuMoDx), adjusted EPS of $2.28 CER. Target 7% CAGR 2024-2028 for core business, 31% operating margin by 2028.

**【CFO Financial Review】**
- 2024 adjusted operating margin 28.7% (+1.8ppt vs 2023), driven by efficiency gains and NeuMoDx phase-out. Free cash flow $506M (+63% YoY).
- Q4 2024 gross margin 67.1% (vs 65.7%), benefiting from QIAstat-Dx mix and cost controls. R&D 9.3% of sales, SG&A 21.8% (down 1.2ppt).
- 2025 targets: 150+ bps margin expansion (to >30%), $300M+ share buybacks, $1B+ returns by 2028.

**【Product Updates】**
- **QIAstat-Dx**: FDA clears 4 U.S. panels, 4,600+ systems installed. QIAstat-Rise launch in U.S. for high-throughput labs.
- **QuantiFERON**: 14% Q4 growth, 40% global latent TB market conversion opportunity. New U.S. guidelines for pediatric testing.
- **QIAcuity**: 12-target flexibility launched, 200+ systems placed Q4. 2025 plan: 100+ new assays, clinical expansion.
- **Sample Tech**: 1,000+ QIAconnect placements. 3 new instruments launching 2025-2026 for microbiome, liquid biopsy.

**【2025 Outlook】**
- **Sales**: 4% CER growth (5% core ex-NeuMoDx). **EPS**: $2.28 CER (+9% vs 2024). **Margins**: >30% operating margin, 31%+ by 2028.
- **Free Cash Flow**: $500M+ annual target. **Share Buybacks**: $300M+ in 2024, $1B+ by 2028.

**【Q&A Highlights】**
- **QuantiFERON**: 2025 double-digit growth expected. German patent win blocks EU competitors.
- **QIAcuity**: 12-target flexibility gains pharma share. 2025: $250M+ digital PCR target.
- **Sample Tech**: 2025 flat to low-single-digit growth, 3 new instruments launching 2025-2026.
- **China**: 5% sales mix, 2025 decline expected. **U.S. Politics**: No immediate impact, long-term R&D tax benefits possible.
- **NeuMoDx**: 2025 sales <$10M, fully phased out by mid-2025.
- **Margins**: 2025 >30% operating margin, 31%+ by 2028. 2028 $2B+ from growth pillars (2024: $1.4B).

QGEN

QGEN fundamentals

Earnings Call

You can ask Aime